Decade after $8B deal, Roche offloads InterMune to mysterious specialty pharma

Roche’s $8 bil­lion In­ter­Mune ac­qui­si­tion, dis­closed a decade ago, is now be­ing hand­ed to a spe­cial­ty phar­ma­ceu­ti­cal com­pa­ny.

Cay­man Is­lands-based Lega­cy Phar­ma is run by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.